abstract |
The problem to be solved by the present invention is to provide a new molecular targeting therapeutic agent for juvenile myelomonocytic leukemia, and the use thereof. The invention relates to a therapeutic agent for juvenile myelomonocytic leukemia containing an ALK tyrosine kinase inhibitor or a JAK2 tyrosine kinase inhibitor. The invention also relates to a novel fusion gene that regulates juvenile myelomonocytic leukemia. |